Biogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Ethic Inc.

Ethic Inc. lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 108.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,912 shares of the biotechnology company’s stock after purchasing an additional 7,743 shares during the period. Ethic Inc.’s holdings in Biogen were worth $2,280,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Larson Financial Group LLC lifted its holdings in Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after buying an additional 141 shares during the last quarter. Lee Danner & Bass Inc. bought a new position in Biogen during the fourth quarter worth $25,000. Colonial Trust Co SC lifted its stake in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 186 shares during the last quarter. OFI Invest Asset Management acquired a new position in Biogen in the fourth quarter worth $32,000. Finally, SRS Capital Advisors Inc. bought a new stake in Biogen during the fourth quarter valued at $33,000. Institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the topic of a number of recent research reports. Hsbc Global Res downgraded shares of Biogen from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 28th. Scotiabank dropped their price objective on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a research note on Thursday, February 13th. Mizuho decreased their target price on Biogen from $207.00 to $169.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Truist Financial dropped their price target on Biogen from $210.00 to $199.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Finally, Oppenheimer set a $205.00 price target on Biogen in a report on Friday, May 2nd. Twenty equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $191.30.

Biogen Price Performance

NASDAQ:BIIB opened at $118.20 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The business’s 50-day moving average price is $128.33 and its 200 day moving average price is $144.11. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $238.00. The firm has a market cap of $17.32 billion, a P/E ratio of 10.56, a PEG ratio of 1.51 and a beta of 0.12.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a net margin of 16.87% and a return on equity of 14.98%. The business had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. During the same quarter last year, the business posted $3.67 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, sell-side analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.